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Abstract: Irritable bowel syndrome (IBS) is a chronic disorder that affects primarily female 
patients and is thought also to afflict approximately 7%–10% of the population of the   Western 
World. Although bowel habits may change over the course of years, patients with IBS are char-
acterized according to their predominant bowel habit, constipation (IBS-C), diarrhea (IBS-D), 
or mixed type (IBS-M), and treatments are focused toward the predominant   symptom. Current 
treatments for IBS-C have included fiber, antispasmodics, osmotic and stimulant   laxatives, and 
the now severely limited 5-HT4 agonist tegaserod. No one agent has been   universally   successful in 
the treatment of this bothersome syndrome and the search for new agents   continues.   Lubiprostone 
(Amitiza), a novel compound, is a member of a new class of agents called prostones and was 
approved for the treatment of chronic idiopathic constipation in 2006 at a dose of 24 µg twice 
daily and then in 2008 for the treatment of IBS-C in women only at a dose of 8 µg twice daily. 
Its purported mechanism is as a type 2 chloride channel activator, but recent evidence suggests 
that it may also work at the cystic fibrosis transport receptor. This article will compare the newly 
proposed mechanism of action of this compound to the purported mechanism and review the 
structure, pharmacology, safety, efficacy, and tolerability of this new therapeutic option. Clinical 
trial data leading to the approval of this agent for the treatment of IBS-C and the gender-based 
understanding of IBS, as well as this agent’s place among existing and emerging therapies, will 
be examined.
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Introduction
Irritable bowel syndrome (IBS) is a chronic condition affecting 7%–10% of the popula-
tion characterized by abdominal pain or discomfort and is associated with a change in 
bowel movement form or frequency (or both) that is usually relieved with defecation.1,2 
It is also not associated with biochemical or structural changes.2 The above statement 
is the definition put forth by the American College of Gastroenterology. However, the 
Rome Committee has advanced a more complex definition based on stool   characteristics 
and subtype – diarrhea, constipation, mixed, and unsubtyped3 (Table 1). By definition, 
patients with IBS with constipation (IBS-C) should have stools that are hard or lumpy 
greater than 25% of the time and loose or mushy less than 25% of the time. Consistency 
is defined using the Bristol Stool Scale (Table 1). IBS-C is usually distinguished from 
chronic idiopathic constipation (CIC) by the presence of abdominal pain. However, in 
reality, the 2 disorders often overlap in the same individual.4International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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It is important to recognize that sufferers with IBS may 
have constipation, diarrhea, or an alternating bowel habit 
associated with pain and bloating that frequently character-
izes acute flares of chronic symptomatology. Studies have 
consistently shown that there is a greater prevalence of IBS 
in women in Western countries (2–3 female:1 male) and that 
women have a statistically significant greater prevalence of 
IBS-C.1,5,6 Women also tend to seek medical help more read-
ily than men, further magnifying the gender differences.7,8 
In a US population where IBS is responsible for 12% of 
primary care visits and up to 28% of all gastroenterology 
visits, it is apparent that IBS and, specifically, IBS-C are 
responsible for a significant health care burden and should 
be of specific concern for those practitioners specializing in 
women’s health.9–12
With the exception of the now severely therapeutically 
limited 5-HT4 agonist tegaserod, treatment options for 
patients with IBS-C have essentially centered on currently 
available treatments used for occasional and chronic con-
stipations often with unsatisfactory results. Frequently, 
studies evaluating most of the currently available agents 
have been of poor quality and uncertain efficacy. Indeed, 
studies have demonstrated that both physicians and 
patients have been dissatisfied with the results of existing 
therapies for the treatment of chronic constipation.13,14 
Since the therapies are similar for both IBS-C and CIC, 
it is not difficult to infer that clinician satisfaction for 
currently available IBS therapies is equally unsatisfactory, 
and survey data from patients indicate that 99% of patients 
have tried traditional agents.14 This article will review 
the therapeutic challenges of treating IBS that led to the 
development of the novel therapy lubiprostone (Amitiza®; 
Sucampo Pharma Americas, Inc., Bethesda, MD, USA 
and Takeda Pharmaceuticals America, Inc., Deerfield, 
IL, USA. Amitiza® is a registered trademark of Sucampo 
Pharmaceuticals. Inc.).15,16 In addition, the structure, phar-
macology, safety, efficacy, and tolerability of lubiprostone 
will be examined, and the newly reported   mechanism of 
action of this agent on the cystic fibrosis transmembrane 
conductance regulator (CFTR)17 in comparison with its 
proposed mechanism of action on the type 2 chloride 
channel (ClC-2) is discussed. The clinical trials data 
that led to the approval of this agent for the treatment of 
IBS-C and the gender-based understanding of IBS will 
be examined. IBS factors influencing the utilization of 
this medication, as well as the place of this agent among 
existing and   emerging therapies, will also be discussed. 
Therapeutic challenges  
in treating IBS-C
The high prevalence, economic burden, and elusive 
pathophysiology of disorder have resulted in a slow but 
steady impetus for research into effective treatments for 
IBS, but the course has been rather tumultuous. Drug com-
panies have been searching for treatment options that would 
relieve the manifold symptoms of IBS sufferers. Traditional 
Table 1 Definition of IBS – American College of Gastroenterology and Rome III definition with Bristol Stool Form Scale
American College of Gastroenterology Rome III definition
Abdominal pain or discomfort associated with altered bowel  
function without evidence of biochemical or structural abnormality.
1.   IBS with constipation (IBS-C) – hard or lumpy stools* $25%  
and loose (mushy) or watery stools† ,25% of bowel movements.‡
2.   IBS with diarrhea (IBS-D) – loose (mushy) or watery stools† $25%  
and hard or lumpy stool* ,25% of bowel movements.‡
3.   Mixed IBS (IBS-M) – hard or lumpy stools* $25% and loose (mushy)  
or watery stools† $25% of bowel movements.‡
4.   Unsubtyped IBS (IBS-U) – insufficient abnormality of stool consistency 
to meet criteria IBS-C, D or M.‡
*Bristol Stool Form Scale 1–2 [separate hard lumps like nuts (difficult to pass) or sausage shaped but lumpy]; †Bristol Stool Form Scale 6–7 (fluffy pieces 
with ragged edges, a mushy stool or watery, no solid pieces, entirely liquid); ‡In the absence of use of antidiarrheals or laxatives. **†Criteria must have 
been present for at least 3 days out of the past 3 months and have an onset >6 months before diagnosis.
The Bristol Stool Form Scale
Type Description
1. Separate hard lumps like nuts (difficult to pass)
2. Sausage shaped but lumpy
3. Like sausage but with cracks on its surface
4. Like sausage or snake, smooth and soft
5. Soft blobs with clear cut edges (passed easily)
6. Fluffy pieces with ragged edges, a mushy stool
7. Watery, no solid pieces, entirely liquidInternational Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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options targeted at the predominant bothersome complaint 
have offered incomplete relief. In IBS-C, patients can suffer 
from mild to severe constipation, as well as from abdominal 
discomfort or pain often compounded by abdominal   bloating, 
feelings of incomplete evacuation, flatus, psychological dis-
tress, and a decreased quality of life (QoL).18,19
Traditional recommendations for the treatment of 
IBS-C have usually centered on beginning with lifestyle 
recommendations, such as increasing fluids, exercise, and 
managing stress. Common treatments for constipation, 
such as increased dietary fiber, are often unsuccessful in 
patients with IBS-C as they may exacerbate the accom-
panying complaints of bloating and flatus. Other treat-
ments targeting constipation in the setting of IBS have 
included bulking agents (isphagula husk), osmotic laxa-
tives (including lactulose and PEG 3350), and tegaserod, 
a 5-HT4 partial agonist. Of these agents, only tegaserod 
has been judged by a panel of gastroenterologists to have 
strong evidence, ie, high-quality, randomized, controlled 
trials that demonstrate not only the goal of increasing 
spontaneous bowel movements (SBMs) but also the goal 
of achieving the overall improvement in global symp-
tom relief and satisfaction with defecation in female 
patients with IBS-C.20,21 However, concerns regarding 
cardiovascular safety resulted in the drug being removed 
from the market in March 2007, when examination of the 
total clinical trial database revealed a higher incidence 
of cardiovascular events (unstable angina, myocardial 
infarction, and cerebrovascular events) in the tegaserod-
treated group compared with the placebo-treated group. 
Currently, this drug is only available from the US Food 
and Drug Administration (FDA) through an emergency 
investigational new drug protocol. The complicated mar-
ket experience of serotonergic drugs (with alosetron for 
IBS-D being placed in a restricted use program and the 
tegaserod experience for IBS-C as described previously) 
have forced the pharmaceutical industry to look at other 
receptor sites in the gastrointestinal tract. Research into 
epithelial function has led scientists to look at chloride 
channels. These channels among other functions man-
age fluid secretion in the gut and this has resulted in the 
development of a new class of agents for the treatment of 
constipation called prostones. Lubiprostone was approved 
in 2006 at a dose of 24 µg twice daily for the treatment of 
chronic constipation in men and women. In April 2008, 
this drug at a dose of 8 µg twice daily became the only 
approved medication by the FDA for treatment of female 
patients with IBS-C.22,23
Pharmacology of lubiprostone
Structure
Lubiprostone is classified as a prostone, a bicyclic fatty 
acid, previously known as difluoropentyl-2-hydroxy-6-
oxooctahydrocyclopenta-heptanoic acid.24 It is derived from 
prostaglandin E1 and is described as a colorless powder that 
is insoluble in water but soluble in ethanol. Chemically, it 
can tautomerize between 2 different forms, the active form 
of lubiprostone is illustrated in Figure 1.
Metabolism and pharmacokinetics
Many commonly used drugs, such as proton pump inhibitors, 
rely on the cytochrome P450 system for their metabolism. 
But, this is not the case for lubiprostone. Animal studies 
have shown lubiprostone is metabolized within the gastro-
intestinal tract, particularly in the stomach and the jejunum, 
by the microsomal carbonyl reductase system. Ninety-four 
percent of the drug is bound to plasma proteins. There is an 
active metabolite, M3, which unlike the parent compound 
is systemically absorbed. The half-life of this metabolite 
is estimated to be 0.9–1.4 hours. Large population studies 
have not been performed, but gender did not seem to influ-
ence the metabolism of this drug. The metabolite, M3, is 
the compound that was used to estimate the area under the 
curve (AUC), maximum plasma concentration (Cmax), and 
half-life (t½) values based on a 24-µg dose of the drug since 
systemic absorption of the drug itself is severely limited. Peak 
plasma levels of M3, after a single oral dose with 24 µg of 
lubiprostone, occurred at approximately 1.10 hours. The Cmax 
was 41.5 pg/mL, and the mean AUC0–t was 57.1 pg.hr/mL. 
The AUC0–t of M3 increased the dose proportionally after 
ingestion of single 24- and 144-µg doses of lubiprostone. 
Unfortunately, the metabolism of the drug in patients with 
renal and hepatic failure has not been tested.25
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Figure 1 Chemical structure of lubiprostone (RU-0211) (C20H32F2O5).
Note: Drug bank: accession number DB01046; CAS registry number 136790-76-6.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Information on pharmacokinetic data of lubiprostone is 
derived from the drug’s package insert because this has not 
been independently evaluated.24 From 0.25 to 168 hours after 
the initial dose administration, blood samples were obtained 
to test for serum levels of lubiprostone concentration. The 
plasma levels were all below 10 pg/mL, ie, all were virtually 
in negligible concentrations, demonstrating a low systemic 
bioavailability after oral administration of the drug. Data on 
food effect have been evaluated using a 72-µg dose of the 
drug, and when given with food, the Cmax was decreased by 
55%. However, AUC0–∞ was unchanged when lubiprostone 
was given with a fatty meal. The clinical importance of the 
effect of meals on drug pharmacokinetics is not clear, but 
the drug was administered with food and water during most 
of the clinical trials. Elimination studies performed with a 
radio-labeled, 72-µg dose of drug demonstrate that 60% of 
the radioactivity is eliminated within 24 hours in the urine 
and 30% of the radioactivity is recovered in the stool within 
168 hours. Only negligible amounts of the drug and its active 
metabolite are traceable in the stool.
Pharmacodynamics
Pharmacodynamic response of lubiprostone has been 
assessed by Camilleri and colleagues.26 They found by 
measuring the frequency and characteristics of bowel 
movements following multiple doses of the drug that the 
maximum-tolerated effective dose for daily treatment was 
24 µg thrice daily. Higher doses increased the side effects 
but not the pharmacodynamic effect. This study also evalu-
ated the effect of lubiprostone on gastrointestinal transit, and 
gastric sensory and motor functions with orally administered 
lubiprostone (24 µg twice daily) in 30 normal individuals. 
When compared with placebo, lubiprostone reduced gastric 
emptying but accelerated small bowel and colonic transits. 
All segments of the colon exhibited the propulsive effects 
of lubiprostone, and in addition, fasting gastric volume was 
found to increase but this did not have any significant effect 
on postprandial gastric volume.
Although there does not appear to be gender-related 
differences in metabolism, recent data from a random-
ized, double-blind, placebo-controlled, single-center, 
parallel-group, pharmacodynamic study of lubiprostone 
in healthy volunteers found that there are significant gen-
der differences in colonic compliance and postprandial 
colonic tone.27
All patients received either 24 µg of lubiprostone or 
placebo. Using barostat-manometry that was endoscopically 
placed, treatment effects on colonic sensation and motility 
were measured. The drug was found to reduce postprandial 
colonic tone (likely responsible for relief of constipation), 
and although not statistically significant, lubiprostone did 
increase the pain sensation thresholds from colonic barostat 
distention in women treated with lubiprostone. The mecha-
nism for the gender differences remains unclear; however, it 
is hypothesized that it may have to do with the effect of sex 
hormones on type 2 chloride (ClC-2) channels. It was also 
found that lubiprostone did not increase the colonic motor 
function, but it was found that the decrease in colonic com-
pliance and tone would facilitate laxation.
Mechanism of action
Thus far, 9 types of chloride channels are known to exist.28 
The most recognized member of this family is the CFTR, 
which is a cyclic adenosine monophosphate (cAMP)-depen-
dent chloride channel, located on the intestinal epithelium 
is believed to be activated by protein kinase A-mediated 
phosphorylation. This chloride channel is known to handle 
a major portion of apical chloride transport in the intestine, 
but other chloride channels are also active.29
Other volume-regulated chloride channels that have been 
described in liver and gastrointestinal cells of both mam-
malian and nonmammalian cells are the type 2 and type 3 
chloride channels (ClC-2 and ClC-3). A variety of actions, 
including intracellular pH regulation, epithelial Cl− transport 
and fluid secretion, exocytosis, maintenance of the membrane 
potential, transmembrane transport of organic osmolytes, and 
cell proliferation, have been purported to be performed by 
these cells. According to the scientific literature, ClC-2 chan-
nels have been found on small and large intestinal epithelial 
cells, as well as on gastrointestinal parietal cells.
In 2004, lubiprostone (SPI-0211, RU-0211), a bicyclic 
fatty acid, was reported to activate apical ClC-2, but not 
CFTR channels on transfected human cells.30 As noted, this 
novel agent was derived from prostaglandin E1 and is a 
member of a class of drugs known as prostones.31 However, 
these prostones, unlike prostaglandins, are not believed to 
stimulate smooth muscle contraction. The postulated mecha-
nism of action is that the active secretion of chloride from 
the epithelial ClC-2 channel into the lumen is followed by 
the passive paracellular secretion of sodium (down the elec-
trochemical gradient) and water, which resulted in isotonic 
fluid in the intestinal lumen increasing the liquidity of the 
intestinal contents. This secretion of fluid is then believed to 
promote increased intestinal transit, perhaps by stimulation 
of local stretch receptors resulting in smooth muscle stimula-
tion (Figure 2).26,32International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Lubiprostone is believed to work by opening the chloride 
channels in the small and large intestines, as well as by open-
ing bicarbonate (HCO3
−) secretory pathways in the duodenum. 
Controversy exists as to which chloride channels are stimu-
lated: the CFTR or the ClC-2 channel. Additional controversy 
also exists as to whether the drug might directly stimulate 
smooth muscle through prostaglandin receptors (ie, a 
G-protein-coupled cAMP signal transduction pathway) 
or whether the ClC-2 channel is expressed in the apical or 
basolateral membrane of mucosal epithelial cells.
Addressing the location of the channels, immunofo-
cal microscopy has demonstrated ClC-2 channels on the 
apical side of human gastrointestinal epithelial cells.30 
Interestingly, evidence also exists that these ClC-2 chan-
nels have been demonstrated on the basolateral membrane 
of distal colonic epithelial cells in guinea pigs33 and in the 
vicinity of tight junctions.34 The explanation that ClC-2 
channels exist on both sides of epithelial cells has been 
that the basolateral channel may serve as an exit pathway 
for Cl− in the distal colon. It has also been suggested that 
chloride channels on both surfaces of the epithelial cells 
might provide a cross talk mechanism to match fluxes at 
the apical and basolateral domains. However, if ClC-2 
channels were to exist only on the basolateral side of the 
membrane, then ClC-2 - mediated chloride transport would 
actually lower the electrochemical potential driving chlo-
ride extrusion across the apical membrane and so would 
be a major issue in view of its therapeutic implications for 
treatment of CIC and IBS-C as discussed previously.
It appears that the differences in the effect of lubi-
prostone may lie in the differences in the biophysical 
properties of the 2 different chloride channels, as well 
as the differences in the concentrations of drug, used in 
different studies and hence the seemingly contradictory 
results. First, chloride channels in 2 types of epithelial 
cell lines were investigated: T84 cells (human-transfected 
adenocarcinoma cell line) and A6 cells (distal nephron cell 
line of an African frog, Xenopus laevis).35,36 Patch-clamp 
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Figure 2 Mechanism of action of lubiprostone across the intestinal epithelial cell. Copyright ©2004. Adapted with permission from American Physiological Society. Cuppoletti 
J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287(5):C1173–
C1183.
Abbreviations: Cl−, chloride; H2O, water; K+, potassium; Na+, sodium; ClC-2, type 2 chloride channel.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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recordings looking at anion flux in both of these cell lines 
revealed that the ClC-2 channels were inwardly rectifying 
the channels that were activated by membrane hyperpolar-
iztion. On the other hand, CFTR channels were outwardly 
rectifying Cl− channels. This led to the conclusion by Bao 
et al36 that ClC-2 channels were ideally suited for aiding 
anion secretion with minimal anion   absorption while 
CFTR channels could make either resorption or secretion 
possible depending on the anion gradient.36
Experiments on chloride secretion either in T84 mono-
layers or in whole-cell patch-clamp studies using a cell line 
transfected with human ClC-2 channels have   demonstrated 
that lubiprostone stimulates Cl− secretion.17,30 In fact, 
  Cuppoletti et al30 found that the half-maximal effective 
  concentration (EC50) of lubiprostone required to stimulate chlo-
ride secretion in the ClC-2 channels in the transfected cells 
was 17 nmol/L and 18 nmol/L in the T84 cells. Bijvelds et al17 
reported that the EC50 for T84 cells was higher and in the 
micromolar range. The experiments of Bao et al36 explained 
this controversy by reporting that concentrations of less than 
100 nmol/L activated ClC-2 channels in the xenopus kidney 
cells (A6 cells) and concentrations greater than 100 nmol/L 
activated the CFTR channel in the same monolayers   suggesting 
at least an explanation for the dichotomy.36
A series of other experiments with forskolin (a chloride 
channel stimulator) using protein kinase A inhibitors17,37,38 and 
tetrotoxin (a toxin that blocks enteric nerve function) indicated 
that the action of lubiprostone is directly on the chloride 
  channel and is independent of a secondary chemical messenger 
(eg, cAMP) or secretomotor function of enteric neurons.
There has also been conjecture about the site of action of 
the drug related to the fact that lubiprostone is a derivative 
of prostaglandin E1, and therefore, structurally similar to 
prostaglandins. Therefore, it has been theorized that the drug 
might directly stimulate smooth muscle through prostaglandin 
receptors (ie, a G-protein-coupled cAMP signal transduction 
pathway). Results from 3 different models (T84 cell monolay-
ers, gastric smooth muscle strips, and duodenal loops in situ) 
are used as evidence supporting a mechanism of action linked 
to prostaglandin receptors.17,39,40 However, animal studies on a 
guinea pig model have not demonstrated that the drug has a 
direct stimulatory effect on gastrointestinal smooth muscles.40,41 
In fact, Cuppoletti et al studied cultured human uterine smooth 
muscle cell and found that lubiprostone acted in a fashion 
directly opposite to that of prostaglandins E1 and E2. The drug 
decreased calcium levels, did not change cAMP levels, and 
caused hyperpolarization rather than depolarization of muscle 
cells.41 Recently, Bassil et al40 demonstrated that though the drug 
caused contraction of stomach longitudinal muscle cells in rat 
and human, it inhibited electrical field-stimulated contractions 
of colonic circular smooth muscle cells. In fact, a prostaglandin 
EP1 receptor antagonist blocked the stimulatory effects of 
lubiprostone on longitudinal muscle, whereas the inhibition of 
circular smooth muscle was reduced by a prostaglandin EP4 
antagonist. Despite this study, the majority of evidence from the 
Cuppoletti study argues against lubiprostone action being medi-
ated by EP receptors.41 In   addition, the fact that tetrodotoxin, a 
  neurotoxin, fails to suppress the secretory response of lubipros-
tone are   inconsistent with this agent having a prostaglandin-like 
excitatory action on secretomotor neurons.
Currently, it appears that the weight of the evidence 
favors that the action of the drug is via the ClC-2 channel, 
but this controversy points to the need for further research 
regarding the role of its influence on CFTR channels, as 
well as on G-protein-coupled prostaglandin receptors. 
Also, since mucosal inflammation may play a role in the 
pathophysiology of IBS, data on file with Sucampo/Takeda 
have demonstrated that activation of ClC-2 by lubiprostone 
has been shown to stimulate recovery of mucosal barrier 
function via the restoration of tight junction protein com-
plexes in ex vivo studies of ischemic porcine intestine.24 
However, the role of tight junctions in IBS-C is unclear.24
Safety and tolerability
As discussed previously, lubiprostone is poorly absorbed 
from the intestinal tract resulting in a reduced potential for 
systemic toxicity, as well as limited availability. The clinical 
trials for both chronic constipation and IBS listed nausea, 
diarrhea, and headache as the most common side effects 
of the drug.24 Not surprisingly, the percentages of patients 
reporting these and other side effects were substantially 
reduced at the lower dose of 8 µg twice daily compared with 
the larger dose of 24 µg twice daily (Table 2). The main side 
effect appears to be nausea and no really good explanation 
exists for this side effect. However, fluid shifts within the 
gut have been postulated to be a possible cause.26
Despite the fact that the drug can cause diarrhea, clinical 
trials did not reveal any significant changes in electrolyte 
levels. Pooled results from both open-label and double-blind 
trials for chronic constipation, ie, at a dose of 24 µg twice 
daily, did not indicate any significant changes in electrolytes 
over a treatment period of 12–48 weeks.42 The percentage 
of patients aged 65 years or older was 10.5% and 18.6%, 
respectively, in the 2 groups of trials.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Electrocardiogram (EKG) changes have not been reported 
in the clinical trials with this drug either in patients with 
constipation (n = 177) or in healthy male and female controls 
(n = 68) (ages not reported).43 EKG changes were recorded 
either after a single 24-µg dose or after a supratherapeutic 
144-µg dose and did not show any changes.
Lubiprostone is metabolized by carbonyl reductase 
and not by the cytochrome P450 system confirming its 
low likelihood of drug – drug interactions.24 Postmarket-
ing data have essentially supported this claim with few 
additional side effects being reported. It is not approved 
for individuals younger than 18 years, and there is no 
clinically available data on patients with hepatic or renal 
impairment.24
Dyspnea is also an important but infrequent side effect 
that can occur. It has been reported in the clinical trials in 
2.5% of the treated patients with CIC and in 0.4% of the 
treated patients with IBS-C. Although this was not classi-
fied as a serious adverse event, some patients discontinued 
treatment because of dyspnea. The dyspnea was described 
by patients as a sensation of chest tightness and difficulty 
in taking in a breath, generally with an acute onset within 
30–60 minutes after taking the first dose. Postmarketing 
reports of dyspnea have also been reported when lubiprostone 
was used at a dose of 24 µg. Although ClC-2 channels exist 
in respiratory epithelium, the mechanism by which dyspnea 
occurs is not known. In vitro experiments conducted on 
respiratory epithelial tissue, where the drug is applied topi-
cally, suggest that the drug can activate chloride secretion 
but do not shed any light on this side effect.44,45 Further, it 
is difficult to postulate how lubiprostone might affect the 
respiratory epithelium in humans who take the drug orally 
when only minuscule amounts are absorbed and even smaller 
amounts of the active metabolite are available. This symptom 
generally resolved within a few hours after patients took the 
dose of medication, but subsequent doses of the drug have 
caused recurrence of the dyspnea. Therefore, patients should 
be cautioned not to take the medication again until evaluated 
by a clinician.
Special populations
Pregnant and lactating women
This drug is classified as pregnancy class C because of its 
possible association with fetal loss in a single-animal study.24 
Why this occurred is not fully understood and is also postu-
lated to have to do with fluid shifts within the body. During 
the preclinical phase of development, rats and mice exposed 
to supratherapeutic doses of lubiprostone did not demonstrate 
any teratogenic effects or other toxicities. However, when 
guinea pigs were exposed to the higher doses, 2 guinea pigs 
developed intrauterine loss. Studies in humans have not been 
performed, but during the clinical testing, 6 women became 
pregnant while on the drug, and per protocol, the drug was 
discontinued.24 Four women had normal deliveries, and the 
fifth woman was progressing as expected without adverse 
events but was lost to follow-up. The sixth pregnancy was 
electively terminated. Although there has been no evidence of 
toxicity in human fetuses till date, it is advised that lubipros-
tone only be used during pregnancy “if the potential benefits 
justify the potential risks to the fetus.”24 The package insert 
recommends that women who could become pregnant should 
have a negative pregnancy test before beginning treatment 
with the drug and also should be capable of complying with 
appropriate contraceptive measures.24
It is not known whether lubiprostone is secreted into 
breast milk. Therefore, taking into account the importance 
of the drug for the mother, it should be recommended to stop 
either the drug or the breast-feeding.24
Children
The drug is not recommended or approved in patients 
younger than 18 years of age.
Table 2 Safety profile of lubiprostone compared in chronic constipation and IBS-C in phase II and phase III trials
Symptom  Placebo *CC  
N = 346 (%)
Lubiprostone 24 µg  
twice daily N = 1113 (%)
Placebo **IBS  
N = 435 (%)
Lubiprostone 8 µg 
twice daily N = 1011 
(%)
Nausea  16 (5.1)  346 (31.1)  17 (4)   81 (8) 
Diarrhea  3 (0.9)  147 (13.2)  17 (4) 71 (7)
Headache  21 (6.6)  147 (13.2)  No reported  Not reported 
Abdominal distention 9 (2.2)  79 (7.1)  22 (5)  50 (5)
Abdominal pain 7 (2.8) 75 (6.7) 9 (2) 30 (3)
Flatulence  6 (1.9) 68 (6.1) Not reported Not reported
vomiting  3 (0.9)  51(4.6)  Not reported  Not reported 
Dizziness  4 (1.3)  46 (4.1)  Not reported  Not reported International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Studies in children are currently underway, but this drug 
is not yet FDA approved for the treatment of chronic consti-
pation or IBS-C in children.
Geriatric use
There is no upper age limit for the use of this medication 
in elderly female patients with IBS-C. In the clinical   trials, 
the safety profile of lubiprostone in the elderly patients 
($65 years of age, 8% of the population were $65 years 
of age and 1.8% of the population were $75 years of age) 
was consistent with the safety profile in the overall study 
population.24 There were no sufficient numbers of patients 
aged 65 years and older to determine whether elderly patients 
respond differently compared with younger patients.
Hepatic and renal impairment
Lubiprostone data are not available in patients with hepatic 
or renal failure.
Gender differences in the 
pathophysiology of IBS
Various pathophysiologic mechanisms have been put forth for 
IBS, including differences in autonomic function, changes in 
visceral pain perception, immune and inflammatory media-
tors, and central processing of visceral stimuli.7 Research into 
the gender differences in functional bowel diseases has pri-
marily been evaluated in IBS and the etiology for the female 
predominance in IBS remains elusive. In   addition, most of 
the data have not been bowel habit specific, but intriguing 
data supporting possible gender differences in motility were 
presented in a 2005 study of patients with slow-transit con-
stipation versus controls, which suggested that endocrine or 
hormonal imbalance might play a role.24,46 In this study, colec-
tomy specimens were obtained from women with intractable 
slow-transit constipation and from women with left colon 
adenocarcinoma (controls). These samples were analyzed 
and compared for possible downregulation of contractile G 
proteins possibly related to overexpression of progesterone 
receptors. However, there were to be no published nondrug 
studies that compared colonic motility in men and women 
with IBS.7
Besides changes in motility, it is known that patients 
with IBS in general have increased visceral perception 
compared with healthy controls,47,48 but few studies have 
compared the difference in visceral perception between men 
and women. Two studies have demonstrated that women 
with IBS have enhanced rectal perception compared with 
men with IBS.49,50
In addition, one study analyzed the effect of the menstrual 
cycle on visceral perception and found that there may be 
an effect on rectal sensitivity in women with IBS but not in 
healthy women. This study examined rectal sensitivity in 
women with IBS compared with controls across the 4 phases 
of the menstrual cycle (menses, follicular phase, luteal phase, 
and premenstrual phase) and demonstrated that perceptual 
thresholds were lower during menses in patients with IBS 
compared with their menstrual cycle phase.51
In addition, there may be gender differences in the central 
processing of visceral stimuli. Two neuroimaging studies 
have found that men and women with IBS did have signifi-
cant differences in brain response to aversive pelvic visceral 
stimuli with men showing greater activation of the dorsal 
anterior cingulate cortex, the lateral prefrontal cortex, and 
the dorsal pons/periacqueductal gray. These areas seem to 
be more involved in endogenous pain inhibition as opposed 
to women with IBS who showed greater activation of the 
limbic and paralimbic regions, areas more involved with the 
pain-facilitation circuit and perhaps more associated with 
emotional response to pain.52,53
An area of particular interest in the pathophysiology of 
IBS is that pharmacotherapy research suggests that gender-
related differences may exist with respect to response to drug 
therapy. Alosetron, a 5-HT3 antagonist, currently available to 
treat severe IBS-D, demonstrated a significant improvement 
in multiple IBS symptoms in women but not in men.54 A 
subsequent study restricted to male patients demonstrated 
significant improvement in IBS pain, discomfort, and stool 
consistency but not in other IBS symptoms.55 Cilansetron, 
another 5-HT3 antagonist for IBS-D that did not make it to 
the market, demonstrated that although there was an overall 
significant improvement in men, the response was less robust 
than in the female patients.56,57 Finally, several studies also 
suggested that the 5-HT4 agonist tegaserod may have greater 
efficacy in female patients.Whether this purely reflects the 
smaller number of male patients studied or sex differences 
in serotonin receptors has yet to be determined, but it is an 
area of interest to be considered when evaluating pharma-
cologic therapy.60
Lubiprostone – efficacy studies
Chronic constipation
Safety and efficacy data on the use of lubiprostone for 
chronic constipation have been reported in one phase II study 
and two phase III studies originally published in abstract 
form.61–63 In 2007, the phase II, multicenter, dose-ranging, 
double-blind, placebo-controlled trial results were published International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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in detailed form.64 In this study, chronic constipation was 
defined as fewer than 3 bowel movements per week for 
6 months or more, with at least 1 symptom associated with 
chronic constipation. Of 129 patients enrolled, 127 patients 
received at least 1 dose of drug and were included in the final 
analysis. Patients first went through a 14-day washout/run-in 
period and then were randomized to receive 24 µg of lubipro-
stone once, twice, or thrice daily versus placebo for 3 weeks. 
Over weeks 1 and 2 of treatment, patients treated with 48 and 
72 µg/day of therapy had a statistically   significant increase 
in the number of SBMs per week compared with placebo.64 
SBMs were the primary outcome measure and this was 
defined as bowel movements not occurring within 24 hours 
of rescue medication use. During week 3, results were no bet-
ter with 48 or 72 µg/day compared with 24 µg/day. Increased 
adverse events (predominantly nausea) at 72 µg/day did not 
provide a clear risk-to-benefit advantage compared with the 
48 mcg/day dosing, hence this dose of 24 µg twice daily was 
chosen for subsequent phase III studies and is the current 
recommended dose in chronic constipation.
Subsequent studies included 2 identical   placebo-controlled 
trials enrolling 479 (237 and 242, respectively) patients.65,66 
Both studies enrolled patients symptomatic with CIC, based 
on modified Rome II criteria, which was defined as fewer than 
3 bowel movements per week for greater than or equal to 6 
months, with at least 1 symptom associated with idiopathic 
constipation (hard or very hard stool, incomplete evacuation, 
and straining with defecation) each for at least 25% of bowel 
movements (BMs).67 A 2-week run-in period preceded a 
4-week randomized treatment phase and was followed by a 
1-week withdrawal. In both studies, patients were primarily 
female (approximately 90%) and Caucasian (76%–86%) and 
they received either lubiprostone (24 µg) or placebo, twice 
daily. The primary end point was SBM frequency after the 
initiation of treatment. Over the entire 4-week trial, lubipro-
stone significantly increased the number of SBMs compared 
with placebo (57%–63%) with a similar response rate in 
male and female patients. Lubiprostone treatment was also 
associated with significant improvements in stool consistency, 
straining, and abdominal symptoms.68,69 Comparable results 
were also found in the elderly patients.70
Long-term, open-label safety and efficacy data from a 
multicenter trial have also been reported.71 A total of 880 
patients with chronic constipation were enrolled in the 3 trials 
and were administered lubiprostone (24 µg, twice daily) for 6 
(n = 308) to 12 (n = 572) months. Johanson and colleagues71 
reported continued efficacy for improving the frequency of 
bowel movements and other constipation-related symptoms. 
The average improvement in constipation severity for all the 
3 studies was 26% at weeks 4–6 (n = 828), 29% at week 24 
(n = 512), and 28% at week 48 (n = 281). Lubiprostone was 
well tolerated, similar to the phase III clinical trials, with nau-
sea being the primary drug-related adverse symptom, reported 
in 27% of patients. However, only 6.6% of patients discon-
tinued the medication. A subanalysis of this data in patients 
older than 65 years revealed that elderly patients had positive 
treatment outcomes and tolerated the drug well.70 In fact, 
nausea was less prominent in the elderly population.
Lubiprostone was also revealed to have no rebound effects 
in a randomized withdrawal study conducted in 128 patients.72 
Following 4 weeks of lubiprostone treatment (24 mcg twice 
daily), patients were randomized to continue active treatment 
for another 3 weeks or receive placebo. At week 7, consis-
tent efficacy was observed in patients on lubiprostone while 
those who had been switched to placebo had fewer SBM, but 
there was no associated rebound effect as SBMs were still 
improved from baseline.72 This lack of rebound effect was also 
confirmed in a recent abstract by Chey et al73 in patients with 
IBS-C. They demonstrated that withdrawal of lubiprostone 
was not associated with symptom rebound following drug 
discontinuation and there was some suggestion that clinical 
benefits may extend beyond drug cessation.
IBS-C
A dose-ranging, double-blind, placebo-controlled study 
in 195 patients was the first study to evaluate the safety 
and efficacy of lubiprostone in the treatment of IBS-C. 
All these patients met Rome III criteria for IBS and were 
randomized to receive placebo or 1 of 3 different lubipros-
tone doses (8, 16, or 24 µg twice daily) for 12 weeks after 
a 4-week screening period.20 Change in abdominal pain/
discomfort during the first 4 weeks of therapy was the pri-
mary end point. Secondary end points included abdominal 
bloating, frequency of SBM, straining at stool, and stool 
consistency. A variety of parameters was monitored and 
included IBS-QoL, symptom diaries, laboratory tests, and 
EKGs. The patients were primarily Caucasians (83%) and 
females (92%). During months 1 and 2, patients showed 
a greater improvement in mean abdominal pain and dis-
comfort scores (P = 0.023 and P = 0.39, respectively) at 
any dose of lubiprostone compared with placebo. This 
difference was not seen at month 3. Even though patients 
at 24 µg twice daily showed the greatest improvement in 
abdominal pain/discomfort, they also had the greatest 
number of adverse events. It was concluded that the 8-mcg 
dose twice daily gave the best combination of safety and International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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efficacy. Although IBS-QoL was examined, it was not 
found to be statistically significant in the lubiprostone 
group. However, the study was not adequately powered 
to detect changes in QoL scores.
Two double-blinded, placebo-controlled studies run in 
parallel led to the approval of lubiprostone by FDA as the 
only prescription drug therapy for IBS-C in the United 
States in April 2008 in women 18 years of age or older.74 
The studies randomized 1,171 patients (92% women; age 
range, 18–65 years) with IBS-C by Rome II criteria to 
receive 8 mcg of lubiprostone or placebo, twice daily for 12 
weeks. The follow-up programs for the studies were slightly 
different, with 1 study having a 4-week open-label exten-
sion. Otherwise, they were identical over the first 12 weeks 
of treatment. Overall efficacy and safety were evaluated in 
1,154 adults who completed the treatment phase of either 
of the 2 trials. The overall response rate after 12 weeks of 
treatment was the primary end point. The statistical analysis 
was combined for the 2 study samples because the initial 
12 weeks of the treatment portions were of the same study 
design and run in parallel. The overall response rate was 
calculated based on weekly electronic diary data using 
the patient’s response to a global symptom relief question 
based on a 7-point, balanced Likert symptom relief scale 
(“significantly worse” to “significantly relieved”): “How 
would you rate your relief of IBS symptoms (abdominal 
discomfort/pain, bowel habits, and other IBS symptoms) 
over the past week compared to how you felt before you 
entered the study?” These end points represented more 
rigorous end points than have been applied to previous 
clinical trials for IBS, and the response rates were quite 
low for both the placebo and active drug groups. However, 
combined analyses demonstrated a higher overall response 
rate in the group of patients receiving lubiprostone than in 
those who had received placebo (17.9% vs 10.1%). Analyz-
ing the data separately showed consistent overall response 
rates between the 2 trials with 16 µg/day of lubiprostone 
significantly more likely compared with placebo to achieve 
a significant result. A patient was considered an “overall 
responder” if the criteria for being designated a “monthly 
responder” was met in at least 2 of the 3 months of the 
study. A “monthly responder” was defined as a patient who 
had reported being “significantly relieved” for at least 2 
weeks of the month or at least “moderately relieved” in all 
4 weeks of that month. A patient was considered a “non-
responder” if they felt worse, increased rescue medication 
usage, or discontinued the drug due to lack of efficacy. 
These stricter standards for determining a responder were 
thought to be the reason for the low placebo response rate 
in this study.
Again, lubiprostone was generally well tolerated and the 
main side effect was nausea (8% drug vs 4% placebo) and 
diarrhea (6% drug vs 4% placebo). In the combined analysis, 
the overall number needed to treat was approximately 13. 
A follow-up, open-label extension study showed that benefits 
continued or improved at 36 weeks and that treatment with 
lubiprostone confers long-term efficacy and safety in patients 
with IBS-C.75
To date, there have been no comparison studies with other 
options for the treatment of IBS-C.
Lubiprostone, IBS symptoms,  
and QoL
Overall, lubiprostone has been shown to have significant ben-
efits on global IBS symptoms.75 In the two 12-week, phase III, 
multicenter, double-blind, randomized, placebo-controlled 
studies of over 1,000 patients (92% female), those receiving 
lubiprostone for IBS (8 µg twice daily) were nearly twice 
as likely to achieve overall response compared with those 
receiving placebo (P = 0.001). Overall response was based 
on global relief of IBS symptoms of abdominal discomfort/
pain, boating, constipation severity, straining, stool consis-
tency, and overall symptom relief. QoL assessed using the 
IBS-QOL questionnaire, a validated tool that has 8 subscales: 
dysphoria, interference with activities, body image, health 
worry, food avoidance, social reaction, sexual, and relation-
ships, was specifically significantly improved in patients 
receiving lubiprostone versus placebo.75 Lubiprostone also 
specifically improved stool consistency, abdominal bloating 
(which highly correlated with improvement in abdominal 
discomfort), and straining; all a wide range of symptoms 
that plague the average female sufferer of IBS.76
Lubiprostone’s place in therapy
It remains unclear why lubiprostone helps relieve global 
symptoms of IBS and its mechanism of action remains 
to be fully elucidated. However, studies are beginning to 
show the possible role of reduced intestinal permeability 
in IBS.77 Patients with IBS often exhibit abnormal gut per-
meability and corresponding inflammatory response.78–80 
These physiologic alterations may contribute to the visceral 
hypersensitivity that typifies this condition. Other possibili-
ties include a decrease in colonic tonicity and alteration of 
pain perception.
As the understanding of the pathophysiology of IBS has 
progressed, research regarding therapies has broadened to International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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include other relevant neurotransmitters and hormones. The 
most promising therapeutic options on the horizon include 
more new selective serotonergic drugs and guanylate cyclase-
C (GC-C) receptor agonists.81 The cardiovascular side effects 
of tegaserod and cisapride have stimulated development of 
agents that are more selective for 5-HT4 and for other sero-
tonergic receptors that might have fewer cardiac effects. Three 
agents show promise in this area, prucalopride, ATI-7505, 
and velusetrag, and these agents have been shown to enhance 
colonic and possibly small bowel motility as well.82 Pruca-
lopride has demonstrated efficacy not only for severe CIC 
in phase IIB and III trials but also for cardiovascular safety 
in elderly individuals (over 80% of whom had a history of 
  cardiac disease).83,84 None of the 100 elderly constipated 
patients studied had changes in their EKGs (ie, no QT pro-
longation) or changes in their Holter data.83,84
Chloride channels have proven to be a popular new target 
and like lubiprostone, the medications linaclotide and guanilib 
work on this target.81 These compounds are GC-C agonists 
that stimulate the production of cyclic-GMP. In a rat model, 
linaclotide, orally administered, has been demonstrated to 
stimulate the secretion of chloride and bicarbonate into 
the intestinal lumen, thereby increasing intestinal fluid 
and gastrointestinal transit.85 This agent is in phase III tri-
als for both IBS-C and CIC and preliminary results look 
very promising. Only the data regarding a dose-ranging, 
placebo-controlled trial regarding CIC have been published, 
and linaclotide produced rapid and sustained improvement 
of bowel habits and abdominal symptoms and global relief 
of symptoms.86 It also improved QoL and was associated 
with few adverse events.86 Like lubiprostone, this medica-
tion has limited systemic absorption and a low side-effect 
profile. Guanilib is still in early phase trials and so its 
efficacy is not known.
Although the future looks promising for the development 
of new agents for the treatment of IBS-C, the good news is 
that lubiprostone is here now and appears to be safe. Post-
marketing data have not revealed any additional concerns. 
Side effects, such as nausea (ameliorated with concurrent 
administration with food), diarrhea, headache, and abdominal 
pain, may limit its use. Lubiprostone may be a gender-specific 
drug with greater efficacy in female patients with IBS-C, but 
the fact that there are fewer males in these studies limits the 
ability to truly make this determination. From a women’s 
health perspective, caution must be exercised in any female of 
child-bearing age as the drug is pregnancy class C and urine 
pregnancy testing before initiating this drug is recommended 
in the prescribing information.24
Lubiprostone provides a much-needed option in the lim-
ited armamentarium of the treatments for IBS-C. Its place in 
therapy has not been clearly delineated, but if patients have 
failed conservative interventions, such as dietary changes or 
bulk-forming agents (fiber supplements and dietary changes) 
and osmotic laxatives (PEG 3350, magnesium hydroxide, 
and lactulose), then lubiprostone should be used. It may be 
necessary in some patients to titrate the dose upward to the 
FDA approved dose of 24 µg twice daily used for chronic 
constipation or to use an intermediate dose. It should be 
remembered that at times it is difficult to distinguish between 
CIC and IBS-C, and titration must be done with care as 
the side-effect profile increases as the dose is increased.24 
Consideration should be given to the fact that conventional 
interventions often exacerbate concurrent symptoms of IBS, 
such as bloating.
Clinicians need to consider a variety of factors when 
making therapeutic choices. The fact that few head-to-head 
comparison studies with other treatment options for IBS-C 
have been performed is a challenging problem and one that 
is not likely to be remedied in the near future. Also, clini-
cians may give more weight to the effectiveness of traditional 
agents then warranted. Economic concerns, such as insurance 
reimbursement, may also influence choice of therapy since 
many plans consider lubiprostone a tertiary agent and do not 
approve its use until patients have failed other therapies. Most 
importantly, clinicians often underestimate the severity of dis-
ease in patients. A recent on-line international survey of 1,966 
patients with IBS used 2 validated instruments (Functional 
Bowel Disorder Severity Index and IBS Severity Scoring 
system) and subjective reporting to assess severity of disease 
(International Foundation for Functional Gastrointestinal Dis-
orders). This study revealed that 20%–55% (depending on the 
instrument used; subjective response −35%) of these individu-
als had severe IBS.87 Previous literatures suggested that only 
5% of the patients had severe disease.88 Despite the severity of 
disease in this surveyed population, only about 2% of patients 
were taking an IBS-targeted drug for their symptoms87 raising 
the issue that these patients may be undertreated. From the 
patient perspective, the respondents to this survey indicated 
that to have an effective treatment and achieve “perfect 
health,” they would be willing to sacrifice 15.1 years of life 
(approximately 25% of remaining years).87
Another study surveying over 250 patients with IBS found 
that health utilities score (a measure of health-related quality 
of life [HRQOL] that ranges between 0 [death] and 1 [perfect 
health]) was 0.7.89 This score is comparable to patients with 
stage III congestive heart failure and rheumatoid arthritis.89 International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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This illustrates that clinicians may need to use tools that assess 
severity of disease in their patients. Patient severity can be 
better predicted for IBS. A recent study in 750 patients with 
IBS revealed that there were 6 factors that predicted patient 
assessed severity of disease independently: (1) abdominal 
pain rating (P , 0.001), (2) belief that “something serious is 
wrong with body” (P , 0.001), (3) straining with defecation 
(P = 0.001), (4) myalgias (P = 0.02), (5) urgency with defeca-
tion (P = 0.03), and (6) bloating (P = 0.05).90 Symptoms of 
abdominal pain, straining at stool, and bloating are symptoms 
commonly seen in patients with IBS-C, and lubiprostone has 
demonstrated efficacy in treating these symptoms, as well as in 
improving QoL. In fact, a review of the data by a panel of gas-
troenterologists using an evidence-based approach supports 
the use of lubiprostone as a first-line therapy in the treatment 
of female patients with IBS-C at a dose of 8 µg twice daily.2 
Thus, it is important for clinicians to better assess severity by 
assessing symptoms more completely and possibly adminis-
tering validated severity questionnaires to more successfully 
use this appropriate and effective treatment.
Disclosures
Dr Lunsford has no conflicts of interest in this work. Dr Harris 
has acted as a consultant for Takeda Pharmaceuticals, Salix, 
Ironwood, Proctor & Gamble, and Prometheus.
References
  1.  Chang L, Heitkemper MM. Gender differences in irritable bowel syn-
drome. Gastroenterology. 2002;123(5):1686–1701.
  2.  Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based 
systematic review on the management of irritable bowel syndrome. 
Am J Gastroenterol. 2009;104 Suppl 1:S8–S35.
  3.  Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, 
Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5): 
1480–1491..
  4.  Drossman D, Li Z, Andruzzi E, et al. U.S, Householder survey of 
functional gastrointestinal disorders. Prevalence, sociodemography and 
health impact. Dig Dis Sci. 1993;38(9):1569–1580.
  5.  Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance, L. Functional 
gastrointestinal disorders in Canada: first population based survey using 
Rome II criteria with suggestions for improving the questionnaire. Dig 
Dis Sci. 2002;47(1):225–235.
  6.  Lee OY, Mayer EA, Schmulson, M, Chang, L, Naliboff B. Gen-
der-related differences in IBS symptoms. Am J Gastroenterol. 
2001;96(7):2184–2193.
  7.  Chang L, Toner BB, Fukodo S, et al. Gender, age, society, culture, and 
the patient’s perspective in the functional gastrointestinal disorders. 
Gastroenterology. 2006;130(5):1435–1446.
  8.  Chial HJ, Camilleri M. Gender differences in irritable bowel syndrome. 
J Gender Specif Med. 2002;5(3):37–45.
  9.  Sandler RS. Epidemiology of irritable bowel syndrome in the United 
States. Gastroenterology. 1990;99(2):409–415..
  10.  Chang L. Review article: epidemiology and quality of life in functional 
gastrointestinal disorders. Aliment Pharmacol Ther. 2004;20 Suppl 
7:S31–S39.
  11.  Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a 
technical review for practice guideline development. Gastroenterology. 
1997;112(6):2120–2137.
  12.  Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable 
bowel syndrome, chronic constipation, functional diarrhea and functional 
abdominal pain. Aliment Pharmacol Ther. 2007;26(2):237–248.
  13.  Schiller LR, Dennis E, Toth G. Primary care physicians consider con-
stipation as a severe and bothersome medical condition that negatively 
impacts patients’ lives [abstract 724]. Am J Gastroenterol. 2004;99 
Suppl:S234–S235.
  14.  Lembo A. Irritable bowel syndrome medications side effects survey. 
J Clin Gastroenterol. 2004;38(9):776–781.
  15.  Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin 
Gastroenterol. 2007;41(4):345–351.
  16.  Lacy BE, Chey WD. Lubiprostone: chronic constipation and irritable 
bowel with constipation. Expert Opin Pharmacother. 2009;10(1): 
143–152.
  17.  Bijvelds MJ, Bot AG, Escher JC, De Jonge HR. Activation of 
intestinal Cl- secretion by lubiprostone requires the cystic fibro-
sis transmembrane conductance regulator. Gastroenterology. 
2009;137(3):976–985.
  18.  Chang L, Lacy BE, Quigley EMM, Schoenfeld PS. Emerging diagnostic 
and treatment strategies for irritable bowel syndrome. Gastroenterol 
Hepatol. 2008;4(10):1–22.
  19.  Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-
related quality of life associated with irritable bowel syndrome: com-
parison with other chronic diseases. Clin Ther. 2002;24(4):674–689.
  20. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clini-
cal trial clinical trial: phase 2 study of lubiprostone for irri-
table bowel syndrome with constipation. Aliment Pharmacol Ther. 
2008;27(8):685–696.
  21.  Khoshoo V , Armstead C, Landry L. Effect of a laxative with and without 
tegaserod in adolescents with constipation predominant irritable bowel 
syndrome. Aliment Pharmacol Ther. 2006:23(1):191–196.
  22.  Lang, L. The Food and Drug Administration approves lubiprostone 
for irritable bowel syndrome with constipation. Gastroenterology. 
2008;135(1):7.
  23.  Schiller LR, Camilleri M. Lubiprostone: viewpoints [comment]. Drugs. 
2006;66(6):880–881.
  24.  AMITIZA® (lubiprostone) [package insert]. Bethesda, MD: Sucampo 
Pharmaceuticals, Inc; 2009.
  25.  Orr, KK. Lubiprostone: a novel chloride channel activator for the treat-
ment of constipation. Formulary. 2006;41(3):118–129.
  26.  Camilleri M, Bharucha A, Ueno R, et al. Effect of a selective chloride 
channel activator, lubiprostone, on gastrointestinal transit, gastric 
sensory and motor functions in healthy volunteers. Am J Physiol Gas-
trointest Liver Physiol. 2006;290(5):G942–G947.
  27.  Sweetser S, Busciglio IA, Camiller M, et al. Effect of a chloride 
channel activator, lubiprostone, on colonic sensory and motor func-
tions in healthy subjects. Am J Physiol Gastrointest Liver Physiol. 
2009;296(2):G295–G301.
  28.  Lipecka J, Bali M, Thomas J, et al. Distribution of CCl-2 chloride 
channel in rat and human epithelial tissue. Am J Physiol Cell Physiol. 
2002;282(4):C805–C816.
  29.  Vandewalle A. Expression and function of CLC and cystic fibrosis 
transmembrane conductance regulator chloride channels in renal epi-
thelial tubule cells pathophysiological implications. Chang Gung Med J.   
2007;30(1):17–25.
  30.  Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 
cell chloride transport and recombinant human ClC-2 chloride currents. 
Am J Physiol Cell Physiol. 2004;287(5):C1173–C1183.
  31.  Lubiprostone:  RU  0211,  SPI  0211.  Drugs R D. 2005;6: 
245–248.
  32.  Grider JR, Jin JG. Distinct populations of sensory neurons mediate the 
peristaltic reflex elicited by muscle stretch and mucosal stimulation. 
J Neurosci. 1994;14 Suppl 5(Pt 1):S2854–S2860.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
373
evaluation of lubiprostone in women with constipation
  33.  Catalan M, Niemeyer MI, Cid LP, et al. Basolateral ClC-2 chloride 
channels in surface colon epithelium: regulation by a direct effect of 
intracellular chloride. Gastroenterology. 2004;126(4):1104–1114.
  34.  Gyomorey K, Yeger H, Ackerly C. Expression of the chloride channel 
ClC-2 in the murine small intestine epithelium. Am J Physiol Cell 
Physiol. 2000;279(6):C1787–C1794.
  35.  Fritsch J, Edelman A. Modulation of the hyperpolarization-activated 
Cl− current in human T84 epithelial cells by phosphorylation. J Physiol. 
1996;490(Pt 1):115–128.
  36.  Bao HF, Li L, Self J, et al. A synthetic prostone activates apical chloride 
channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol. 
2009;295(2):G234–G251.
  37.  Tewari KP, Malinowska DH, Sherry AM, Cuppoletti J. PKA and 
  arachidonic acid activation of human recombinant ClC-2 chloride 
channels. Am J Physiol Cell Physiol. 2000;279(1):C40–C50.
  38.  Fei G, Wang YZ, Liu S, et al. Stimulation of mucosal secretion by 
lubiprostone (SPI-0211) in guinea pig small intestine and colon. 
Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G823–G832.
  39.  Mizumori M, Akiba Y, Kaunitz JD. Lupiprostone stimulates duodenal 
bicarbonate secretion in rats. Dig Dis Sci. 2009;54(10):2063–2069.
  40.  Bassil AK, Boman RA, Jarvie EM, et al. Activation of prostaglandin 
EP receptors by lubiprostone in rat and human stomach and colon. 
Br J Pharmacol. 2008;154(1):126–135.
  41.  Cuppoletti J, Malinowsk DH, Chakrabarti J, Ueno R. Effects of lubi-
prostone on human uterine smooth muscle cells. Prostaglandins Other 
Lipid Mediat. 2008;86(1–4):56–60.
  42.  Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel 
type-2 chloride channel (Clc-2) activator, does not affect serum 
electrolyte balance in elderly and non-elderly patients with chronic 
idiopathic constipation. Gastroenterology. 2007;132(4 Suppl 
2):A191–A192.
  43.  Sprenger C, Copa A, Morganroth J, et al. Effect of lubiprostone, a 
unique agent for the treatment of chronic idiopathic constipation on 
clinical electrocardiogram results. Gastroenterology. 2007;132(4 
Suppl 2):A325.
  44.  MacDonald KD, McKenzie KR, Henderson MJ, et al. Lubiprostone 
activates non-CFTR-dependent respiratory epithelial chloride secre-
tion in cystic fibrosis Mice. Am J Physiol Lung Cell Mol Physiol. 
2008;295(9):L933–L940.
  45.  Joo NS, Wine JJ, Cuthbert AW. Lubiprostone stimulates secretion from 
tracheal submucosal glands of sheep, pigs and humans. Am J Physiol 
Lung Cell Mol Physiol. 2009;296(5):L811–L824.
  46.  Xiao ZL, Pricolo V , Biancani P, Behar J. Role of progesterone signaling 
in the Regulation of G-protein levels in female chronic constipation. 
Gastroenterology. 2005;128(3):667–675.
  47.  Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for recto-
sigmoid distention in irritable bowel syndrome. Gastroenterology. 
1990;98(4):1187–1192.
  48.  Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation 
induces rectal hyperalgesia in patients with irritable bowel syndrome. 
Gastroenterology. 1997;112(1):55–63.
  49.  Ragnarrsson G, Hallbook O, Bodemar G. Abdominal symptoms are not 
related to anorectal function in the irritable bowel syndrome. Scand J 
Gastroenterol. 1999;34(3):250–258.
  50.  Chang L, Mayer EA, Labus J, et al. Effect of sex on perception of 
rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul 
Integr Comp Physiol. 2006;29(2):R277–R284.
  51.  Houghton LA, Lea R, Jackson N, Whorwell PU. The menstrual cycle 
affects rectal sensitivity in patients with irritable bowel syndrome but 
not healthy volunteers. Gut. 2002;50(4):471–474.
  52.  Berman S, Munakata J, Naliboff BD, et al. Gender differences in 
regional brain response to visceral pressure in IBS patients. Eur J Pain. 
2000;4(2):157–172.
  53.  Naliboff BD, Berman S, Chang L, et al. Sex-related differences in 
IBS patients:central processing of visceral stimuli. Gastroenterology. 
2003;124(7):1738–1747.
  54.  Camilleri, M, Mayer EA, Drossman DA, et al. Improvement in pain 
and bowel function in female irritable bowel patients with alosetron, 
a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13(9): 
1149–1159.
  55.  Chang L, Ameen VZ, Dukes GE, McSorley D, Mayer EA. A 
dose-  ranging, phase II study of the efficacy and safety of alosetron 
hydrochloride (Lotronex) in men with diarrhea-predominant IBS. Am 
J Gastroenterol. 2005;100(1):115–123.
  56. Bradette M, Moennikes H, Carter F, et al. Cilansetron in irri-
table bowel syndrome with diarrhea predominance (IBS-D). 
Efficacy and safety in a 6 month study. Gastroenterology. 2004; 
126(4 Suppl 2):A42.
  57.  Coremnans G, Clouse RE, Carter F, Krause, G, Caras S, Steinborm C. 
Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males 
with irritable bowel syndrome with diarrhea predominance (IBS-D). 
Gastroenterology. 2004;126(4 Suppl 2):A643.
  58.  Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5HT 
(4) receptor partial agonist, relieves symptoms in irritable bowel syn-
drome patients with abdominal pain, bloating and constipation. Aliment 
Pharmacol Ther. 2001;15(10):1655–1666.
 59.  Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double-blind, pla-
cebo controlled randomized study to evaluate the efficacy, safety and 
tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 
2003;52(5):671–676.
  60.  Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter 
polymorphism pharmacogenetics in diarrhea-predominant irritable 
bowel syndrome. Gastroenterology. 2002;123(2):425–432.
  61.  Johanson JF, Gargano MA, Patchen ML, Ueno R. Efficacy and safety 
of a novel compound, RU-0211, for the treatment of constipation. 
Gastroenterology. 2002;122(1 Suppl 4):A315.
  62.  Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III efficacy and 
safety of RU-0211, a novel chloride channel activator, for the treatment 
of constipation. Gastroenterology. 2003;124(4 Suppl 1):A48.
  63.  Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III study of 
lubiprostone, a chloride channel-2 (CIC-2) activator for treatment of 
constipation: Safety and primary efficacy. Am J Gastroenterol. 2005; 
100(9 Suppl 9s):S328.
  64.  Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel 
activator, in adult patients with chronic constipation: a double-blind, 
placebo-controlled, dose-ranging study to evaluate efficacy and safety. 
Aliment Pharmacol Ther. 2007;25(11):1351–1361.
  65.  Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and 
safety of lubiprostone in chronic constipation. Dig Dis Sci. 
2010;55(4):1090–1097.
  66.  Johanson JF, Morton D, Geenen J, Ueno R. Multi-center, 4-week, 
double-blind, randomized, placebo-controlled trial of lubiprostone, a 
locally-acting type-2 chloride channel activator in patients with chronic 
constipation. Am J Gastroenterol. 2008;103(1):170–177.
  67.  Thompson WG, Longstreth G, Drossman DA, Heaton K, Irvine EJ, 
Muller-Lissner S. Functional bowel disorders and functional abdomi-
nal pain. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, 
Whitehead WE, editors. Rome II: The Functional Gastrointestinal 
Disorders. McLean VA: Dagnon Associates, Inc; 2000:351–432.
  68.  Anonymous. Lubiprostone (amitiza) for chronic constipation. Med Lett 
Drugs Ther. 2006;48(1236):47–48.
  69.  Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. 
Phase III efficacy and safety of RU-0211, a novel chloride channel 
activator, for the treatment of constipation. Gastroenterology. 2003; 
124(4 Suppl 1):A104.
  70.  Ueno R, Panas R, Wahle A, Zhu Y, Holland PC. Long-term 
safety and efficacy of lubiprostone for the treatment of chronic 
constipation in elderly subjects. Gastroenterology. 2006; 
130(4 Suppl 2):A188.
  71.  Johanson JF, Gargano MA, Patchen ML, Ueno R. Multi-center open 
label study of lubiprostone for the treatment of chronic constipation. 
Am J Gastroenterol. 2005;100(9 Suppl 9):S331.International Journal of Women’s Health
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-womens-health-journal
The International Journal of Women’s Health is an international, peer-
reviewed open-access journal publishing original research, reports, 
reviews and commentaries on all aspects of women’s healthcare includ-
ing gynecology, obstetrics, and breast cancer. Subject areas include: 
Chronic conditions (migraine headaches, arthritis, osteoporosis); 
Endocrine and autoimmune syndromes; Sexual and reproductive 
health; Psychological and psychosocial conditions. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
374
Lunsford and Harris
  72.  Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III, ran-
domized withdrawal study of RU-0211, a novel chloride channel 
activator for the treatment of constipation. Gastroenterology. 2004; 
126(4 Suppl 2):S100
  73.  Chey WD, Saad RJ, Panas R, Wahle A, Ueno R. Discontinuation of 
lubiprostone treatment for irritable bowel syndrome with constipa-
tion is not associated with symptom increase or recurrence: results 
from a randomized withdrawal study. Gastroenterology. 2008;   
134(4 Suppl 1):A401.
  74.  Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: l  ubiprostone in 
patients with constipation-associated irritable bowel syndrome – results 
of two randomized, placebo-controlled studies. Aliment Pharmacol 
Ther. 2009;29(3):329–341.
  75.  Drossman DA, Chey WD, Scott C, Panas R, Ueno R. Health-related 
quality of life in adults with irritable bowel syndrome with constipation: 
results of combined analysis of two phase 3 studies with lubiprostone. 
Gastroenterology. 2008;134(4 Suppl 1):A469.
  76. Chey WD, Drossman DA, Scott C, Panas R, Ueno R. What symptoms 
drive global symptom improvement with lubiprostone in patients 
with irritable bowel syndrome and constipation: data from two mul-
ticenter, randomized, placebo-controlled trials. Gastroenterology. 
2008;134(4 Suppl 1):A28.
  77.  Camilleri  M,  Gorman  H.  Intestinal  permeability  and  IBS. 
Neurogastroenterol Motil. 2007;19(7):545–552.
  78.  Dunlop SP, Hepben J, Campbell E, et al. Abnormal intestinal 
permeability in subgroups of diarrhea-predominant irritable bowel 
syndrome. Am J Gastroenterol. 2006;101(6):1288–1204.
  79.  Marshall JK, Thabane M, Garg AX, Clark W, Medings J, Collins SM. 
Intestinal permeability in patients with irritable bowel syndrome after 
a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. 
Aliment Pharmacol Ther. 2004;20(11–12):1317–1322.
  80.  Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal 
enteroendocrine cells, T lymphocytes, and increased gut permeability 
following acute Campylobacter enteritis and in post-dysenteric irritable 
bowel syndrome. Gut. 2000;47(5):804–811.
  81.  Crowell MD, Harris LA, Lunsford TN, DiBaise J. Emerging drugs 
for chronic constipation. Expert Opin Emerg Drugs. 2009;14(3): 
493–504.
  82.  Camilleri M. Review article: new receptor targets for medical therapy in 
irritable bowel syndrome. Aliment Pharmacol Ther. 2010;31(1):35–46.
  83.  Camilleri M, Kerstens R, Beyens G, Robinson P, Vandeplassche L. 
A double-blind, placebo controlled trial to evaluate the safety and 
tolerability of prucalo-pride oral solution in constipated elderly 
patients living in a nursing facility. Gastroenterology. 2009; 
136 Suppl 1:S240.
  84.  Camilleri M, Beyens G, Kertsens R, Vandeplassche L. Long-term follow 
up of safety and satisfaction with bowel function in response to oral 
prucalopride in patients with chronic constipation. Gastroenterology. 
2009;136 Suppl 1:S160.
  85.  Forte LR Jr. Uroguanylin and guanylin peptides: pharmacology and experi-
mental and therapeutics. Pharmacol Ther. 2004;104(2):137–162.
  86.  Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients 
with chronic constipation. Gastroenterology. 2010;138(3):886–895.
  87.  Drossman DA, Morris CB, Schneck S, et al. International survey of 
patients with IBS: symptom features and their severity, health status 
treatments, and risk taking to achieve clinical benefit. J Clin Gastro-
enterol. 2009;43(6):541–550.
  88.  Drossman DA, Thompson WG. The irritable bowel syndrome: review 
and a graduated multicomponent treatment approach. Ann Intern Med. 
1992;116(12 Pt 1):1009–1016.
  89.  Spiegel B, Harris LA, Lucak S, et al. Developing valid and reliable 
health utilities in irritable bowel syndrome: results from the IBS PROOF 
cohort. Am J Gastroenterol. 2009;104(8):1984–1991.
  90.  Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors 
of patient-assessed illness severity in irritable bowel syndrome. Am J 
Gastroenterol. 2008;103(10):2536–2543.